drugset / Trial / NCT04457531

LiuWeiLuoBi Granule for the Treatment of Diabetic Peripheral Neuropathy

NCT04457531 ↗

Phase 0 Unknown 60 enrolled China Academy of Chinese Medical Sciences
RandomizedParallel-groupOpen-labelTreatment

Summary

Based on network pharmacology, Liuweiluobi Granule was screened to treat diabetes peripheral neuropathy with deficiency of the spleen and kidney and stasis-heat syndrome.In the preliminary animal experiment, it suggested that this granule had a significant protective effect on the peripheral motor nerves of diabetic peripheral neuropathy and the effect of anti-inflammation, and the prescription did not induce the death of zebrafish at a concentration of 1000 ug/mL, without any obvious toxicity. This study aims to evaluate the efficacy of Liuweiluobi Granule in improving neurotransmission function in patients with diabetic peripheral neuropathy through a pilot, randomized controlled study.

Timeline

Start
2020-10-26
Primary completion
2023-09
Completion
2023-12

Drugs

EvaluationDrugModalityDoseRoute
Subject LiuWeiLuoBi Granule Traditional medicine (herbal / TCM) — —